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Abstract. A total of  19 patients with advanced squamous-  
cell carc inoma o f  the head and neck who  had not pre- 
viously been exposed  to chemotherapy  were treated with 
brequinar  sodium as first-line chemotherapy.  Brequinar  
was given intravenously at a median weekly  dose of  
1,200 mg/m2. The toxicity was moderate,  with 7 patients 
(37%) experiencing grade 3 or 4 toxicity. In all, 16 patients 
who were evaluable  for eff icacy showed no object ive re- 
sponse. W e  conclude that brequinar given at this dose and 
on this schedule has no significant activity in advanced 
squamous-cel t  carc inoma of  the head and neck. 
Introduction 
Brequinar  sodium is a novel  antimetaboli te  that interferes 
with dihydrooratate  dehydrogenase,  and enzyme  that is 
crucial for pyr imidine  biosynthesis  [4]. Brequinar  was se- 
lected for clinical deve lopment  because of  its broad anti- 
tumor  activity in murine  models  (L 1210 leukemia  and B 16 
melanoma)  and human  tumor  xenografts  [breast (MX-1),  
colon (CX-1),  lung (LX-1),  and gastric (BL/STX-1)]  [7]. 
A number  of  phase  I studies using different dose levels 
and schedules have  been reported [ I - -3 ,  5, 8, 9]. In these 
phase I studies, the limiting toxicities included th rombocy-  
topenia and mucosit is/stomatit is .  Minor  responses were 
seen in advanced bladder,  lung, lymphoma,  and thyroid 
carc inoma [3, 5, 9]. The  weekly  schedule was selected for 
phase II  evaluation because  of  the superior dose intensity 
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achieved in compar ison with that previously  obtained on 
the phase I schedules. In addition, the pharmacokinet ie  
profi le indicated a half-life o f  15 h, resulting in prolonged 
drug exposure when this schedule was used [3]. Preclinical 
studies also suggested that eff icacy was achieved by  pro- 
longed exposure  [7, 11]. 
On the basis of  the phase I experience,  the recom- 
mended phase II starting dose and schedule was 
1,800 mg/m2 weekly  [3, 5]. Early in the phase  I I  evaluation 
of  brequinar in several  tumor  categories, this starting dose 
resulted in unacceptable  toxicity [6]. Therefore,  the starting 
dose was reduced to 1,200 m g / m  2 weekly.  
The present  mult icenter  study was designed to evaluate 
the activity of  brequinar in patients with advanced 
squamous-cel l  carc inoma of  the head and neck who had 
received no prior chemotherapy.  
Patients and methods 
The criteria for inclusion in the study were a performance status of _< 2 
(WHO scale), a life expectancy of >8 weeks, a serum bilirubin value of 
<1.5 rag/all, a serum creatinine level of <2.0 mg/dl, an absolute granulo- 
cyte count of >I,500 cells/ram 3, a platelet count of >100,000hnm 3, and 
the presence of bidimensionally measurable disease. Informed consent 
was given by all patients in accordance with regulatory agency require- 
m e n t s .  
Brequinar was given intravenously once weekly at a starting dose of 
1,200 mg/m 2 in 500 ml normal saline over 1-2 h. The dose of brequinar 
was escalated or decreased according to predetermined criteria and de- 
pending on the toxicities experienced during the preceding course. When 
necessary, dosing was delayed until the patient had recovered from 
toxicities. Toxicity was coded by NCI common toxicity criteria (2/18/88 
version). 
Patients were interviewed and examined prior to each dose of chemo- 
therapy. Laboratory studies, including complete blood cell, differential, 
and platelet counts, were repeated once a week. Total protein, albumin, 
calcium, inorganic phosphorus, glucose, blood urea nitrogen, creatinine, 
uric acid, total bilirubin, alkaline phosphatase, lactic dehydrogenase, and 
electrolytes were assessed every 4 weeks. 
Response was evaluated every 4 weeks by appropriate radiologic 
studies and clinical measurement of bidimensional lesions. Criteria for 
defining response were standard except that a palpable reduction in liver 
size was not used to designate a partial response, Patients were consid- 
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Table 1. Patient's characteristics and treatment data Table 2. Toxicity encountered in the present study 
Total patients 19 
Evaluable patients 16 
Sex (M/F) 15/4 
Median age (years) 59 (range, 44-77) 





Radiation therapy 18 
Sites of metastases 
Lymph nodes 2 (11%) 
Bone 2 (11%) 
Lung 5 (26%) 
Mediastinum 1 (5%) 
Skin/subcutaneous tissue 5 (26%) 
Other 3 (16%) 
Number of doses given: 
Total 104 
Median 4 
Range 1 - 17 
Number of patients receiving: 
Dose escalation 5 
Dose reduction 4 
a WHO [12] 
ered to be evaluable for response if they had received at least one dose of 
brequinar and had undergone a subsequent assessment of their measur- 
able disease. Patients who died of their disease without undergoing such 
an assessment were considered to be evaluable and classified as having 
progressive disease. 
Resul t s  
From November  1988 to June 1989, 19 patients with ad- 
vanced squamous-cell carcinoma of the head and neck 
entered in the study. Data on the patients and their treat- 
ment characteristics are listed in Table 1. The patients had 
an excellent performance status and limited exposure to 
prior therapy. The predominant sites of  measurable disease 
were the lung and the skin/subcutaneous tissue. The 
19 patients, received a total of  104 doses of  brequinar 
(median, 4; range, 1 -17) .  Dose escalation was possible in 
five patients and dose reduction was required in four cases. 
Two patients received only one dose. The median weekly 
dose was 1,200 rag/m2. 
Of  the 19 patients entered in the study, 16 were evalua- 
ble for response; 1 patient each was deemed inevaluable 
due to the absence of a measurable lesion, to early non-dis- 
ease-related death, and to our inability to obtain follow-up 
measurements. No objective response was observed, and 
eight patients displayed stabilization of their disease. 
All 19 patients were evaluable for toxicity. In general, 
the toxicity encountered in this phase I1 trial was moderate. 
The major nonhematologic and hematologic toxicities en- 
countered are listed in Table 2. No drug-related death oc- 
curred. However, two patients were removed from the 
Toxic effect Number of patients by maximal grade 
Grade 1 Grade 2 Grade 3 Grade 4 
Nausea/vomiting 5 5 0 0 
Mucositis/stomatitis 9 1 3 0 
Rash 6 0 0 1 
Diarrhea 2 2 0 1 
Thrombocytopenia 3 1 4 1 
Anemia 2 5 1 0 
Leukopenia 3 6 0 0 
Granulocytopenia 1 1 0 0 
study because of grade 4 toxicities. One patient experi- 
enced grade 4 diarrhea and thrombocytopenia after four 
doses; this patient received a cumulative brequinar dose of 
7,200 mg. The second patient experienced a grade 4 rash 
after the second dose (cumulative dose, 2,400 mg). The 
rash associated with high-dose intermittent administration 
of brequinar has been described elsewhere [ 10]. 
Eight episodes of grade 3 toxicity occurred in five 
patients. Six of  the seven patients who experienced grade 
3 - 4  toxicity did so during the first four weekly doses. The 
patients who experienced grade 3 - 4  toxicity received a 
median of 3 doses (range, 1 -9) ,  whereas those who did not 
develop grade 3 - 4  toxicity received a median of 6 doses 
(range, 1-17) .  The median weekly dose given to 
these seven patients was 1,378 mg/m2 (range, 9 7 2 -  
1,800mg/m2) and the median cumulative dose was 
3,817 mg (range, 1,200-17,064 mg). The corresponding 
doses for the patients who experienced toxicity graded _< 2 
were a median weekly dose of 1,200 mg/m2 (range, 9 6 0 -  
2,160 mg/m 2) and a median cumulative dose of 6,910 mg 
(range, 1,200 - 20,400 mg). 
In all, 11 patients discontinued therapy because of dis- 
ease progression. The remaining patients were removed 
from treatment for the following reasons: grade 4 toxicity 
(n = 2), non-disease-related death (n = 1), loss to follow-up 
(n = 1), refusal of further therapy (n = 2), and stabilization 
of disease after 12 weeks of therapy (n = 2). 
D i s c u s s i o n  
The absence of objective responses in 16 evaluable patients 
excludes (with 95% confidence) a response rate of  20% 
(one-sided 95% confidence limit, 17.1%). On the basis of  
these results, we conclude that brequinar given at this dose 
and on this schedule does not have sufficient activity to 
warrant further evaluation in patients with advanced 
squamous-cell carcinoma of the head and neck. 
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